Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $102000.0.

  • Sutro Biopharma's Cash from Financing Activities fell 8997.05% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $84000.0, marking a year-over-year decrease of 9990.76%. This contributed to the annual value of $94.1 million for FY2024, which is 3162.39% down from last year.
  • Sutro Biopharma's Cash from Financing Activities amounted to $102000.0 in Q3 2025, which was down 8997.05% from -$60000.0 recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Cash from Financing Activities peaked at $137.7 million during Q2 2023, and registered a low of -$5.7 million during Q3 2023.
  • Over the past 5 years, Sutro Biopharma's median Cash from Financing Activities value was $760000.0 (recorded in 2022), while the average stood at $14.9 million.
  • As far as peak fluctuations go, Sutro Biopharma's Cash from Financing Activities soared by 1416410.26% in 2022, and later tumbled by 13915.28% in 2024.
  • Quarter analysis of 5 years shows Sutro Biopharma's Cash from Financing Activities stood at $506000.0 in 2021, then soared by 2315.22% to $12.2 million in 2022, then tumbled by 125.57% to -$3.1 million in 2023, then surged by 99.23% to -$24000.0 in 2024, then skyrocketed by 525.0% to $102000.0 in 2025.
  • Its Cash from Financing Activities stands at $102000.0 for Q3 2025, versus -$60000.0 for Q2 2025 and $66000.0 for Q1 2025.